Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Corporate Governance > Committee Composition

Committee Composition

  Audit Nominating and Corporate Governance Compensation
Luigi Lenaz,, MD   Committee Chair for Nominating and Corporate Governance Committee Member of Compensation Committee
Luigi Lenaz, Lead Director

Dr. Lenaz served as Spectrum's Chief Scientific Officer from February 2005 to June 2008 and as President of Spectrum's Oncology Division from 2000 to 2005.  From 1997 to 2000, Dr. Lenaz served as Senior Vice President of Clinical Research, Medical Affairs at SuperGen, Inc., a NASDAQ listed pharmaceutical company dedicated to cancer drug development.  From 1978 to 1997, Dr. Lenaz held several senior management positions with Bristol-Myers Squibb, a NYSE-listed pharmaceutical company, including Senior Vice-President of Oncology Franchise Management from 1990 to 1997 and Director of Scientific Affairs, Anti-Cancer from 1985 to 1990.  Dr. Lenaz is also a prominent researcher, having conducted research in the areas of pharmacology, experimental chemotherapy, histology, general physiology, and experimental therapeutics at various institutions for cancer research, including Roswell Park Memorial Institute, Memorial Sloan-Kettering Cancer Center and the National Cancer Institute in Milan.  He is a member of several scientific societies, including the American Association for Cancer Research, American Association for Clinical Oncology, European Society for Medical Oncology, and International Association for the Study of Lung Cancer.  Dr. Lenaz served as a director of Pharmaco-Kinesis Corporation, a privately held medical device company, from 2009 to 2014.
 
Dr. Lenaz is a graduate of Liceo Scientifico A. Righi in Bologna, Italy and he received his medical degree from the University of Bologna Medical School in 1966.  Dr. Lenaz is a renowned and accomplished oncologist who brings to the Board of Directors over 35 years’ experience in the pharmaceutical industry and a wealth of knowledge in the field of cancer drug development.  Dr. Lenaz's qualifications to serve on the Board of Directors include his expertise in the development of cancer drugs, his tenure as our Chief Scientific Officer, his management experience with Bristol-Myers Squibb, and his prominent research in the field of oncology.

Raymond W. Cohen Member of Audit Committee   Committee Chair for Compensation Committee
Stuart M. Krassner,, ScD, PsyD Member of Audit Committee    
Anthony E. Maida III,, PhD, MA, MBA Committee Chair for Audit Committee Member of Nominating and Corporate Governance Committee  
Dolatrai M. Vyas, PhD   Member of Nominating and Corporate Governance Committee Member of Compensation Committee
Committee Chair = Chair Committee Member = Member

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
7.54
Change:
+ 0.16
Day High:
7.59
Day Low:
7.34
Volume:
1,265,348
4:00 PM ET on Jun 26, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR